JP2019510731A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510731A5
JP2019510731A5 JP2018528557A JP2018528557A JP2019510731A5 JP 2019510731 A5 JP2019510731 A5 JP 2019510731A5 JP 2018528557 A JP2018528557 A JP 2018528557A JP 2018528557 A JP2018528557 A JP 2018528557A JP 2019510731 A5 JP2019510731 A5 JP 2019510731A5
Authority
JP
Japan
Prior art keywords
composition according
molecular weight
polyalkylene glycol
segment
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018528557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510731A (ja
JP6812436B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050139 external-priority patent/WO2017139849A1/en
Publication of JP2019510731A publication Critical patent/JP2019510731A/ja
Publication of JP2019510731A5 publication Critical patent/JP2019510731A5/ja
Application granted granted Critical
Publication of JP6812436B2 publication Critical patent/JP6812436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018528557A 2016-02-19 2017-02-17 抗ウイルス薬およびウイルス感染症の治療方法 Active JP6812436B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900595 2016-02-19
AU2016900595A AU2016900595A0 (en) 2016-02-19 Method for treatment of cancer or viral infection
AU2016902715A AU2016902715A0 (en) 2016-07-11 Method for treatment of cancer or viral infection
AU2016902715 2016-07-11
PCT/AU2017/050139 WO2017139849A1 (en) 2016-02-19 2017-02-17 Anti-virus agent and method for treatment of viral infection

Publications (3)

Publication Number Publication Date
JP2019510731A JP2019510731A (ja) 2019-04-18
JP2019510731A5 true JP2019510731A5 (enExample) 2020-02-06
JP6812436B2 JP6812436B2 (ja) 2021-01-13

Family

ID=59624666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018528557A Active JP6812436B2 (ja) 2016-02-19 2017-02-17 抗ウイルス薬およびウイルス感染症の治療方法

Country Status (7)

Country Link
US (2) US11045491B2 (enExample)
EP (1) EP3416656B1 (enExample)
JP (1) JP6812436B2 (enExample)
CN (1) CN108472311B (enExample)
AU (2) AU2017220391B2 (enExample)
ES (1) ES2867453T3 (enExample)
WO (1) WO2017139849A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295116B2 (en) * 2020-01-31 2024-05-01 Recce Pharmaceuticals Ltd A process for preparing a biologically active copolymer that includes an acrolein derivative and a polyalkylene oligomer
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
WO2025129262A1 (en) * 2023-12-21 2025-06-26 Gramele Industrial Holdings Pty Ltd Methods of ameliorating microbial growth

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2112381B (en) * 1981-09-30 1986-08-28 Nat Res Dev Cyclic ether and thioether derivatives for use as diluents in sustained release compositions
PH23983A (en) 1986-12-23 1990-02-09 Biopolymers Ltd Biostatic and biocidal composition
CN87108390A (zh) * 1986-12-23 1988-09-21 生物聚合物有限公司 抑制生物和杀生物的组合物
AUPN327695A0 (en) 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
EP0792895B1 (de) 1996-02-22 2001-05-16 Degussa AG Acrolein freisetzende Copolymere
US6060571A (en) 1996-02-22 2000-05-09 Degussa Aktiengesellschaft Acrolein-releasing copolymers
US6060235A (en) * 1997-09-19 2000-05-09 Geltex Pharmaceuticals, Inc. Antiviral polymers comprising acid functional groups and hydrophobic groups
WO2001060874A1 (en) * 2000-02-16 2001-08-23 Chemeq Ltd. Antimicrobial polymeric compositions
US7629002B2 (en) 2000-02-16 2009-12-08 Chemeq Ltd. Antimicrobial polymeric compositions and method of treatment using them
AUPS327102A0 (en) * 2002-06-28 2002-07-18 Chemeq Ltd Method of treatment or prophylaxis of gastrointestinal diseases
CA2472685C (en) * 2002-01-18 2010-07-20 Chemeq Ltd Method of treatment of gastrointestinal disease and polymeric composition for use therein
ATE461226T1 (de) * 2003-11-06 2010-04-15 Chemeq Ltd Verfahren zur herstellung von polyacrolein
WO2009059350A1 (en) * 2007-11-07 2009-05-14 Recce Pty Ltd Anti-microbial polymers and their compositions
EP2186521A1 (en) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
WO2011047420A1 (en) * 2009-10-19 2011-04-28 Chemeq Ltd Cosmetic compositions
AU2010100972A4 (en) * 2009-10-19 2010-10-07 Chemeq Ltd Topical antimicrobial compositions
WO2015160940A1 (en) * 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents
JP6605602B2 (ja) * 2014-11-18 2019-11-13 レッセ ファーマシューティカルズ リミテッド 細菌感染の治療のためのコポリマーおよび方法

Similar Documents

Publication Publication Date Title
Hadidi et al. Emerging plant proteins as nanocarriers of bioactive compounds
JP2014240439A5 (enExample)
RU2019114665A (ru) Противовирусные композиции для лечения инфекций, связанных с коронавирусами
HRP20200925T1 (hr) Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina
JP2019510731A5 (enExample)
JP2013253101A5 (enExample)
JP2014148535A5 (enExample)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2012012418A5 (enExample)
IL217243A (en) Theophane 2-carboxylic acid derivatives, including pharmaceutical preparations and their uses for the preparation of flaviviridiae virus infections and hepatitis c virus infections
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
JP2010537989A5 (enExample)
JP2016518442A5 (enExample)
JP2015529685A5 (enExample)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2010285436A5 (enExample)
EA201100809A1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ, ВЫСОКООЧИЩЕННЫЙ, СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2017512194A5 (enExample)
JP2017507142A5 (enExample)
RU2016117398A (ru) Композиции полиинозиновой-полицитидиловой кислоты (поли (и:ц)) для лечения инфекций верхних дыхательных путей
NZ720863A (en) Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment
JP2010524882A5 (enExample)
CN102488697B (zh) 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用
RU2017142710A (ru) Состав полиинозиновой-полицитидиловой кислоты (поли-(i:с)) на основе горохового крахмала для профилактики и/или лечения инфекций верхних дыхательных путей